Aurora Cannabis Announces Fiscal 2025 Second Quarter Results
Aurora Cannabis reported strong fiscal Q2 2025 results with record adjusted EBITDA of $10.1 million, up 210% year-over-year. Total net revenue reached $81.1 million, a 29% increase driven by 41% growth in global medical cannabis and 21% growth in plant propagation. International revenue grew 93% to $35 million, exceeding Canadian Medical revenue for the first time. The company maintains a strong balance sheet with $152 million in cash and a debt-free cannabis business. Medical cannabis contributed 76% of consolidated net revenue with a 68% adjusted gross margin. The company reaffirms its target of positive free cash flow by December 31, 2024.
Aurora Cannabis ha riportato risultati solidi per il secondo trimestre fiscale del 2025, con un EBITDA rettificato record di 10,1 milioni di dollari, in aumento del 210% su base annua. Il fatturato netto totale ha raggiunto 81,1 milioni di dollari, con un incremento del 29% alimentato da una crescita del 41% nel mercato globale della cannabis medicinale e del 21% nella propagazione vegetale. I ricavi internazionali sono cresciuti del 93%, arrivando a 35 milioni di dollari, superando per la prima volta i ricavi provenienti dalla cannabis medicinale in Canada. L'azienda mantiene un forte bilancio con 152 milioni di dollari in contante e un'attività di cannabis senza debiti. La cannabis medicinale ha contribuito al 76% del fatturato netto consolidato, con un margine lordo rettificato del 68%. L'azienda riconferma il suo obiettivo di generare flusso di cassa libero positivo entro il 31 dicembre 2024.
Aurora Cannabis reportó resultados sólidos para el segundo trimestre fiscal de 2025, con un EBITDA ajustado récord de $10.1 millones, un aumento del 210% interanual. Los ingresos netos totales alcanzaron $81.1 millones, un incremento del 29% impulsado por un crecimiento del 41% en el cannabis medicinal global y un 21% en la propagación de plantas. Los ingresos internacionales crecieron un 93% hasta $35 millones, superando por primera vez los ingresos médicos en Canadá. La compañía mantiene un balance sólido con $152 millones en efectivo y un negocio de cannabis sin deudas. El cannabis medicinal contribuyó con el 76% de los ingresos netos consolidados, con un margen bruto ajustado del 68%. La empresa reafirma su objetivo de flujo de caja libre positivo para el 31 de diciembre de 2024.
Aurora Cannabis는 2025 회계년도 제2분기 강력한 실적을 보고하며, 조정된 EBITDA가 1,010만 달러로 연간 210% 증가했다고 발표했습니다. 총 순수익은 8,110만 달러에 달하며, 이는 글로벌 의약용 대마초의 41% 성장과 식물 번식의 21% 성장을 통해 29% 증가한 수치입니다. 해외 매출은 93% 증가하여 3,500만 달러에 달하며, 최초로 캐나다 의약용 매출을 초과했습니다. 회사는 1억 5,200만 달러의 현금을 보유하고 있으며, 부채 없는 대마초 사업으로 강력한 재무 상태를 유지하고 있습니다. 의약용 대마초는 총 순수익의 76%를 차지하며, 조정된 총 이익률은 68%입니다. 회사는 2024년 12월 31일까지 긍정적인 자유 현금 흐름 목표를 재확인합니다.
Aurora Cannabis a annoncé des résultats solides pour le deuxième trimestre fiscal 2025, avec un EBITDA ajusté record de 10,1 millions de dollars, en hausse de 210 % par rapport à l'année précédente. Le chiffre d'affaires net total a atteint 81,1 millions de dollars, soit une augmentation de 29 % tirée par une croissance de 41 % du cannabis médical mondial et de 21 % de la propagation des plantes. Les revenus internationaux ont augmenté de 93 % pour atteindre 35 millions de dollars, dépassant pour la première fois les revenus médicaux canadiens. L'entreprise maintient un solide bilan avec 152 millions de dollars en liquidités et une activité de cannabis sans dettes. Le cannabis médical a contribué à 76 % du chiffre d'affaires consolidé, avec une marge brute ajustée de 68 %. L'entreprise réaffirme son objectif de flux de trésorerie libre positif d'ici le 31 décembre 2024.
Aurora Cannabis hat starke Ergebnisse für das zweite Finanzquartal 2025 gemeldet, mit einem Rekord-EBITDA von 10,1 Millionen Dollar, was einem Anstieg von 210% im Vergleich zum Vorjahr entspricht. Der gesamte Nettoumsatz erreichte 81,1 Millionen Dollar, ein Anstieg von 29%, der durch ein Wachstum von 41% im globalen medizinischen Cannabis und 21% im Pflanzenanbau angetrieben wurde. Der internationale Umsatz wuchs um 93% auf 35 Millionen Dollar und übertraf damit erstmals die Einnahmen aus medizinischem Cannabis in Kanada. Das Unternehmen hat eine starke Bilanz mit 152 Millionen Dollar in bar und einem schuldenfreien Cannabis-Geschäft. Medizinisches Cannabis trug 76% zum konsolidierten Nettoumsatz bei, mit einer bereinigten Bruttomarge von 68%. Das Unternehmen bekräftigt sein Ziel eines positiven freien Cashflows bis zum 31. Dezember 2024.
- Record adjusted EBITDA of $10.1M, up 210% YoY
- Total net revenue increased 29% YoY to $81.1M
- International revenue grew 93% to $35M
- Medical cannabis revenue up 41% YoY to $61.3M
- Strong balance sheet with $152M cash and debt-free cannabis business
- Medical cannabis gross margin improved to 68% from 63% YoY
- Consumer cannabis revenue decreased 13% YoY to $10.4M
- Consumer cannabis gross margin declined to 14% from 27% YoY
- Negative free cash flow of $26.4M in Q2
- Increased SG&A expenses by 14% YoY to $31.7M
Insights
Aurora Cannabis delivered a remarkably strong Q2 FY2025 with several positive indicators. Net revenue grew
Key strengths include international medical cannabis revenue surpassing Canadian revenue for the first time, reaching
The strategic pivot toward international medical cannabis markets is proving highly successful. Significant growth in key markets like Australia, Germany, Poland and the UK demonstrates strong market penetration and execution. The
The company's diversification through Bevo's plant propagation business adds stability, showing
NASDAQ | TSX: ACB
- Record Adjusted EBITDA1 of
, a YoY increase of$10.1 Million 210% - Quarterly Net Revenue1 up
29% YoY to , with$81.1 Million 41% growth in Global Medical Cannabis - Re-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024
- Maintains Strong Balance Sheet with
~ of Cash and a Debt-Free Cannabis Business2$152 Million
"Our strong quarterly results demonstrate Aurora's leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as
"With two quarters remaining in the fiscal year, we are proud to have delivered record adjusted EBITDA1 and believe fiscal 2025 is anchored by our commitment to strategic growth, operational excellence, and the continued strength of our balance sheet," Mr. Martin concluded.
1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures. |
2 Aurora's only remaining debt is non-recourse debt of |
Second Quarter 2025 Highlights
(Unless otherwise stated, comparisons are made between fiscal Q2 2025, Q1 2025, and Q2 2024 results and are in Canadian dollars)
Consolidated Revenue and Adjusted Gross Profit:
Total net revenue1 was
Consolidated adjusted gross margin before fair value adjustments1 was
Medical Cannabis:
Medical cannabis net revenue1 was
The increase in net revenue1 of
Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue reached
Consumer Cannabis:
Aurora's consumer cannabis net revenue1 was
Adjusted gross margin before fair value adjustments1 on consumer cannabis net revenue1 was
Plant Propagation:
Plant propagation net revenue1 was wholly comprised of the Bevo business, and contributed
Adjusted gross margin before fair value adjustments1 on plant propagation revenue was
Selling, General and Administrative ("SG&A"):
Adjusted SG&A1 was
Net Income (Loss):
Net income from continuing operations for the three months ended September 30, 2024 was
Adjusted EBITDA:
Adjusted EBITDA1 increased
Fiscal Q3 2025 Expectations:
In Q3 2025, we expect to see continued strong net revenue1 and adjusted gross margins1 across our global medical cannabis business, supported by net revenue1 growth in
For plant propagation, we expect to see seasonally reduced net revenues1 and adjusted gross profit1 that will be in line with historical seasonal trends as
Positive adjusted EBITDA1 is expected to continue, while free cash flow1 is projected to be positive due to strong net revenue1 and continued spend discipline, resulting in strong adjusted gross margins.
Key Quarterly Financial Results
($ thousands, except Operational Results) | Three months ended | ||||||
September 30, 2024 | June 30, 2024 | $ Change | % Change | September 30, 2023(3) | $ Change | % Change | |
Financial Results | |||||||
Net revenue (1a) | ( | (3 %) | 29 % | ||||
Medical cannabis net revenue (1a) | 30 % | 41 % | |||||
Consumer cannabis net revenue (1a) | ( | (10 %) | ( | (13 %) | |||
Plant propagation revenue | ( | (63 %) | 21 % | ||||
Adjusted gross margin before FV adjustments on total net revenue (1b) | 54 % | 43 % | N/A | 11 % | 51 % | N/A | 3 % |
Adjusted gross margin before FV adjustments on cannabis net revenue (1b) | 57 % | 53 % | N/A | 4 % | 55 % | N/A | 2 % |
Adjusted gross margin before FV adjustments on medical cannabis net revenue (1b) | 68 % | 69 % | N/A | (1 %) | 63 % | N/A | 5 % |
Adjusted gross margin before FV adjustments on consumer cannabis net revenue (1b) | 14 % | 24 % | N/A | (10 %) | 27 % | N/A | (13 %) |
Adjusted gross margin before FV adjustments on plant propagation net revenue (1b) | 19 % | 18 % | N/A | 1 % | 22 % | N/A | (3 %) |
Adjusted SG&A expense(1d) | 1 % | 14 % | |||||
Adjusted EBITDA (1c) | 107 % | 210 % | |||||
Free cash flow (1e) | ( | ( | (507 %) | ( | 10 % | ||
Balance Sheet | |||||||
Working capital (1f) | ( | (4 %) | 54 % | ||||
Cannabis inventory and biological assets (2) | 3 % | 55 % | |||||
Total assets | ( | (4 %) | ( | (1) % | |||
1) | These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure: | |
a) | Refer to the "Revenue" and "Cost of Sales and Gross Margin" section for a reconciliation of cannabis net revenue to the IFRS equivalent. | |
b) | Refer to the "Adjusted Gross Margin" section for reconciliation to the IFRS equivalent. | |
c) | Refer to the "Adjusted EBITDA" section for reconciliation to the IFRS equivalent. | |
d) | Refer to the "Operating Expenses" section for reconciliation to the IFRS equivalent. | |
e) | Refer to the "Liquidity and Capital Resources" section for a reconciliation to the IFRS equivalent. | |
f) | "Working capital" is defined as Current Assets less Current Liabilities as reported on the Company's Consolidated Statements of Financial Position. | |
2) | Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets. | |
3) | Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Conference Call
Aurora will host a conference call today, Wednesday, November 6, 2024, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation.
DATE: | Wednesday, November 6, 2024 |
TIME: | 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time |
WEBCAST: |
This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Statements
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's Q2 FY2025 results, statements under the heading "Fiscal Q3 2025 Expectations", including as related to net cannabis revenue growth and adjusted gross margins, revenue and gross profit in the plant propagation segment, and expectations for positive adjusted EBITDA and free cash flow, statements regarding the Company's continued commitment to operational excellence and strategic growth, and statements regarding the Company's conference call to discuss results.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and nongovernment consumer sales channels, management's estimates of consumer demand in
The Company's AIF, MD&A and annual financial statements, which have been filed on SEDAR+ and with the SEC, are also available on the Company's website www.auroramj.com and shareholders may receive hard copies free of charge upon request by contacting aurora@icrinc.com.
Non-GAAP Measures
This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis for the fiscal period ended September 30, 2024 (the "MD&A") is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the SEC's EDGAR website at www.sec.gov.
Net Revenue, Adjusted Gross Profit and Margin
Net revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:
($ thousands) | Three months ended | Six months ended | |||
September 30, | June 30, | September 30, | September 30, | September 30, | |
Medical cannabis net revenue(1) | |||||
Canadian medical cannabis net revenue | 26,269 | 27,117 | 25,382 | 53,386 | 50,822 |
International medical cannabis net revenue | 35,047 | 20,084 | 18,135 | 55,131 | 34,009 |
Total medical cannabis net revenue | 61,316 | 47,201 | 43,517 | 108,517 | 84,831 |
Consumer cannabis net revenue(1) | |||||
Consumer cannabis net revenue(1) | 10,422 | 11,533 | 11,959 | 22,078 | 25,102 |
Wholesale bulk cannabis net revenue(1) | 750 | 1,620 | 489 | 2,370 | 860 |
Total cannabis net revenue(1) | 72,488 | 60,354 | 55,965 | 132,842 | 110,793 |
— | |||||
Plant propagation revenue | 8,634 | 23,081 | 7,154 | 31,715 | 27,058 |
Total net revenue(1) | 81,122 | 83,435 | 63,119 | 164,557 | 137,851 |
(1) | Net revenue is a Non-GAAP Measure and is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the "Cost of Sales and Gross Margin" section of this MD&A for a reconciliation to IFRS equivalent. |
(2) | Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Adjusted EBITDA
Adjusted EBITDA is a Non-GAAP Measure and can be reconciled with net income (loss), the most directly comparable GAAP financial measure, as follows:
($ thousands) | Three months ended | Six months ended | |||
September 30, | June 30, 2024 | September 30, | September 30, | September 30, | |
Net income (loss) from continuing operations | 1,675 | 4,844 | 439 | 6,519 | (19,758) |
Income tax expense (recovery) | (1,072) | 2,857 | 128 | 1,785 | 224 |
Other income (expense) | (2,995) | (6,824) | (11,392) | (9,819) | (5,712) |
Share-based compensation | 4,468 | 3,019 | 4,568 | 7,487 | 6,849 |
Depreciation and amortization | 6,380 | 6,494 | 9,151 | 12,874 | 17,392 |
Acquisition costs | 991 | 1,001 | 563 | 1,992 | 789 |
Inventory and biological assets fair value and impairment adjustments | 529 | (12,348) | (4,705) | (11,819) | (8,109) |
Business transformation related charges (1) | 3,394 | 4,381 | 6,801 | 7,775 | 12,518 |
Out-of-period adjustments (2) | — | — | 478 | — | 808 |
Non-recurring items (3) | (3,248) | 1,463 | (2,766) | (1,785) | 883 |
Adjusted EBITDA (4) | 10,122 | 4,887 | 3,265 | 15,009 | 5,884 |
(1) | Business transformation related charges includes costs related to closed facilities, certain IT project costs, costs associated with the repurposing of Sky and Sun, severance and retention costs in connection with the business transformation plan, and costs associated with the retention of certain medical aggregators. Some prior period amounts have been adjusted for changes in presentation. |
(2) | Out-of-period adjustments reflect adjustments to net loss for the financial impact of transactions recorded in the current period that relate to prior periods. Some prior period amounts have been adjusted for changes in presentation. |
(3) | Non-recurring items includes one-time excise tax refunds, non-core adjusted wholesale bulk margins, inventory count adjustments resulting from facility shutdowns and inter-site transfers, litigation and non-recurring project costs. |
(4) | Adjusted EBITDA is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the MD&A. Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs, and non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation. |
Adjusted SG&A
Adjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows:
Three months ended | Six months ended | ||||
($ thousands) | September 30, | June 30, 2024 | September 30, | September 30, | September 30, |
General and administration | 22,036 | 22,524 | 22,527 | 44,560 | 43,876 |
Sales and marketing | 13,721 | 14,024 | 12,611 | 27,745 | 25,281 |
Business transformation costs | (4,035) | (4,868) | (6,515) | (8,903) | (10,578) |
Out-of-period adjustments | — | — | (478) | — | (808) |
Non-recurring costs | — | (284) | (412) | (284) | (1,005) |
Adjusted SG&A (1) | 31,722 | 31,396 | 27,733 | 63,118 | 56,766 |
(1) | Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
(2) | Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Free Cash Flow
The table below outlines free cash flow for the periods ended:
Three months ended | Six months ended | ||||
($ thousands) | September 30, | June 30, 2024 | September 30, | September 30, | September 30, |
Cash provided by (used in) operating | 5,295 | (1,822) | (12,883) | 3,473 | (25,888) |
Changes in non-cash working capital | (29,588) | 10,682 | (14,781) | (18,906) | (10,967) |
Net cash provided by (used in) operating activities from continuing operations | (24,293) | 8,860 | (27,664) | (15,433) | (36,855) |
Less: maintenance capital expenditures(1) | (2,140) | (2,370) | (1,815) | (4,510) | (4,310) |
Free cash flow(2) | (26,433) | 6,490 | (29,479) | (19,943) | (41,165) |
(1) | Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth. |
(2) | Free cash flow is a Non-GAAP Measure and is not a recognized, defined, or a standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
Working Capital
Working capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows:
($ thousands) |
September 30, | Three months ended June 30, 2024 |
September 30, |
Total current assets | 417,675 | 439,366 | 387,981 |
Total current liabilities | (109,095) | (116,803) | (152,558) |
Working capital(1) | 308,580 | 322,563 | 235,423 |
(1) | Working capital for the three months ended September 30, 2023 has been adjusted. Refer to discussion under "Liquidity and Capital Resources" section of the MD&A. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-fiscal-2025-second-quarter-results-302297178.html
SOURCE Aurora Cannabis Inc.
FAQ
What was Aurora Cannabis (ACB) revenue in Q2 2025?
How much did ACB's medical cannabis revenue grow in Q2 2025?
What was Aurora Cannabis (ACB) adjusted EBITDA in Q2 2025?